Status:
COMPLETED
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12-45 years
Phase:
PHASE2
Brief Summary
Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris
Detailed Description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab in adolescent and adult participants with acne vulgaris (AV). This...
Eligibility Criteria
Inclusion
- Key
- Diagnosis of moderate to severe facial AV
- Facial IGA) score of 3 (moderate) or 4 (severe)
- At least 20 and no more than 100 inflammatory lesions on the face
- No more than 100 non-inflammatory lesions on the face.
- No more than 5 nodules (≥5 millimeter \[mm\]) on the face
- Key
Exclusion
- A participant with acne fulminans or conglobate or secondary acne will be excluded.
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 29 2022
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT04856917
Start Date
May 15 2021
End Date
March 29 2022
Last Update
September 22 2025
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 10-114
Hot Springs, Arkansas, United States, 71913
2
Site 10-111
Fountain Valley, California, United States, 92708
3
Site 10-106
Sherman Oaks, California, United States, 91403
4
Site 10-113
Sweetwater, Florida, United States, 33172